Compare Stocks: CVAC, RLAY, TLX, and LEGN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CVAC CureVac	$4.66	$4.66	$3.13 ▼ $5.72	$960.17M	1.77	992,546 shs	N/A
LEGN Legend Biotech	$18.64 -2.9%	$21.75	$16.24 ▼ $37.50	$3.61B	0.4	1.62 million shs	4.28 million shs
RLAY Relay Therapeutics	$18.87 -0.1%	$19.38	$3.88 ▼ $21.27	$4.14B	1.69	2.66 million shs	4.16 million shs
TLX Telix Pharmaceuticals	$11.29 -5.1%	$11.23	$6.28 ▼ $12.48	$3.84B	-0.17	184,032 shs	414,798 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CVAC CureVac	0.00%	0.00%	0.00%	0.00%	-13.38%
LEGN Legend Biotech	0.00%	-13.38%	-8.04%	-48.03%	-44.31%
RLAY Relay Therapeutics	0.00%	-0.89%	-5.32%	+27.41%	+364.78%
TLX Telix Pharmaceuticals	0.00%	-5.44%	-8.43%	+18.10%	+16.51%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CVAC CureVac	$4.66	$4.66	$3.13 ▼ $5.72	$960.17M	1.77	992,546 shs	N/A
LEGN Legend Biotech	$18.64 -2.9%	$21.75	$16.24 ▼ $37.50	$3.61B	0.4	1.62 million shs	4.28 million shs
RLAY Relay Therapeutics	$18.87 -0.1%	$19.38	$3.88 ▼ $21.27	$4.14B	1.69	2.66 million shs	4.16 million shs
TLX Telix Pharmaceuticals	$11.29 -5.1%	$11.23	$6.28 ▼ $12.48	$3.84B	-0.17	184,032 shs	414,798 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CVAC CureVac	0.00%	0.00%	0.00%	0.00%	-13.38%
LEGN Legend Biotech	0.00%	-13.38%	-8.04%	-48.03%	-44.31%
RLAY Relay Therapeutics	0.00%	-0.89%	-5.32%	+27.41%	+364.78%
TLX Telix Pharmaceuticals	0.00%	-5.44%	-8.43%	+18.10%	+16.51%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CVAC CureVac	1.00	Sell	N/A	N/A
LEGN Legend Biotech	2.47	Hold	$53.14	185.10% Upside
RLAY Relay Therapeutics	2.93	Moderate Buy	$25.92	37.34% Upside
TLX Telix Pharmaceuticals	2.86	Moderate Buy	$20.40	80.69% Upside

Current Analyst Ratings Breakdown

Latest CVAC, RLAY, TLX, and LEGN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/11/2026	LEGN Legend Biotech	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$78.00 ➝ $74.00
9/4/2026	LEGN Legend Biotech	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$65.00
9/4/2026	LEGN Legend Biotech	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$65.00
9/2/2026	TLX Telix Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$20.00
9/1/2026	LEGN Legend Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/21/2026	TLX Telix Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D) ➝ Hold (C-)
8/20/2026	TLX Telix Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/20/2026	RLAY Relay Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/20/2026	RLAY Relay Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$28.00 ➝ $29.00
8/20/2026	TLX Telix Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$22.00
8/18/2026	LEGN Legend Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 9/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CVAC CureVac	$70.74M	14.78	$0.99 per share	4.73	$3.36 per share	1.39
LEGN Legend Biotech	$1.03B	3.51	N/A	N/A	$5.43 per share	3.43
RLAY Relay Therapeutics	$15.35M	269.39	N/A	N/A	$3.27 per share	5.77
TLX Telix Pharmaceuticals	$803.79M	4.77	$0.04 per share	267.77	$1.23 per share	9.18

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CVAC CureVac	$175.50M	$0.72	6.47	N/A	N/A	199.92%	-23.03%	-19.09%	N/A
LEGN Legend Biotech	-$296.80M	-$0.25	N/A	15.93	N/A	-7.21%	-8.71%	-5.40%	11/11/2026 (Estimated)
RLAY Relay Therapeutics	-$276.48M	-$1.57	N/A	N/A	N/A	N/A	-42.27%	-38.67%	11/5/2026 (Estimated)
TLX Telix Pharmaceuticals	-$7.12M	N/A	N/A	188.17	N/A	N/A	N/A	N/A	N/A

Latest CVAC, RLAY, TLX, and LEGN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/11/2026	Q2 2026	LEGN Legend Biotech	$0.07	$0.09	+$0.02	$0.18	$355.96 million	$387.50 million
8/6/2026	Q2 2026	RLAY Relay Therapeutics	-$0.3911	-$0.41	-$0.0189	-$0.41	$0.96 million	$0.35 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CVAC CureVac	N/A	N/A	N/A	N/A	N/A
LEGN Legend Biotech	N/A	N/A	N/A	N/A	N/A
RLAY Relay Therapeutics	N/A	N/A	N/A	N/A	N/A
TLX Telix Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CVAC CureVac	0.03	3.70	3.69
LEGN Legend Biotech	N/A	3.04	2.94
RLAY Relay Therapeutics	N/A	18.27	18.27
TLX Telix Pharmaceuticals	1.16	2.01	1.85

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CVAC CureVac	17.26%
LEGN Legend Biotech	70.89%
RLAY Relay Therapeutics	96.98%
TLX Telix Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
CVAC CureVac	2.15%
LEGN Legend Biotech	0.02%
RLAY Relay Therapeutics	5.04%
TLX Telix Pharmaceuticals	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CVAC CureVac	880	224.34 million	219.52 million	No Data
LEGN Legend Biotech	2,965	193.77 million	193.73 million	Optionable
RLAY Relay Therapeutics	192	219.14 million	208.10 million	Optionable
TLX Telix Pharmaceuticals	1,184	339.78 million	N/A	N/A

CVAC, RLAY, TLX, and LEGN Headlines

Recent News About These Companies

Telix Pharmaceuticals (NASDAQ:TLX) Sees Large Volume Increase - Still a Buy?

September 11 at 12:00 PM | marketbeat.com

Telix Pharmaceuticals (NASDAQ:TLX) Sets New 1-Year High - What's Next?

September 9, 2026 | marketbeat.com

Telix to Present at the Morgan Stanley 24th Annual Global Healthcare Conference and H.C. Wainwright 28th Annual Global Investment Conference

September 9, 2026 | globenewswire.com

TLX stock clocks 5% gain this week ahead of FDA decision on brain cancer imaging agent

September 4, 2026 | msn.com

Telix Pharmaceuticals Limited (TLX)

September 4, 2026 | finance.yahoo.com

Telix Pharmaceuticals (NASDAQ:TLX) Shares Gap Up - Here's What Happened

September 4, 2026 | americanbankingnews.com

HC Wainwright Reaffirms "Buy" Rating for Telix Pharmaceuticals (NASDAQ:TLX)

September 4, 2026 | americanbankingnews.com

Telix shares are up 98%: Is there more upside to come?

September 3, 2026 | msn.com

Telix Pharmaceuticals Limited (NASDAQ:TLX) Given Average Recommendation of "Moderate Buy" by Brokerages

September 3, 2026 | americanbankingnews.com

Telix Pharmaceuticals Limited (NASDAQ:TLX) Receives Average Recommendation of "Moderate Buy" from Analysts

September 3, 2026 | marketbeat.com

Telix Pharmaceuticals shares rise 5.3% as analyst highlights BiPASS trial and FDA pathway

September 2, 2026 | msn.com

Telix Pharmaceuticals (NASDAQ:TLX) Shares Gap Up - What's Next?

September 2, 2026 | marketbeat.com

Telix Pharmaceuticals' (TLX) Buy Rating Reaffirmed at HC Wainwright

September 2, 2026 | marketbeat.com

Telix Completes Enrollment in Phase 3 BiPASS Study, Aligns with FDA on NDA Pathway

September 1, 2026 | globenewswire.com

Telix Appoints Gill As Board Chairman

September 1, 2026 | rttnews.com

Telix Appoints David Gill as Chair

August 31, 2026 | globenewswire.com

Telix Pharmaceuticals (NASDAQ:TLX) Stock Price Down 4.5% - Time to Sell?

August 26, 2026 | marketbeat.com

Telix Pharmaceuticals: Execution Is The Name Of The Game Here

August 24, 2026 | seekingalpha.com

Telix Pharmaceuticals (NASDAQ:TLX) Shares Gap Down - Here's What Happened

August 21, 2026 | marketbeat.com

HotCopper highlights: Zip dominates investor attention as Telix, Liontown and American Tungsten trend

August 21, 2026 | msn.com

Why were Telix shares just downgraded?

August 20, 2026 | fool.com.au

New MarketBeat Followers Over Time

Media Sentiment Over Time

CVAC, RLAY, TLX, and LEGN Company Descriptions

CureVac NASDAQ:CVAC

$4.66 0.00 (0.00%)

As of 09/11/2026

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.

Legend Biotech NASDAQ:LEGN

$18.64 -0.55 (-2.87%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$18.99 +0.35 (+1.86%)

As of 09/11/2026 07:39 PM Eastern

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.

Relay Therapeutics NASDAQ:RLAY

$18.87 -0.02 (-0.11%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$18.85 -0.02 (-0.11%)

As of 09/11/2026 07:30 PM Eastern

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Telix Pharmaceuticals NASDAQ:TLX

$11.29 -0.61 (-5.13%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$11.16 -0.13 (-1.14%)

As of 09/11/2026 07:53 PM Eastern

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CVAC, RLAY, TLX, and LEGN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CVAC, RLAY, TLX, and LEGN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CVAC, RLAY, TLX, and LEGN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CVAC, RLAY, TLX, and LEGN Company Descriptions

CureVac NASDAQ:CVAC

Legend Biotech NASDAQ:LEGN

Relay Therapeutics NASDAQ:RLAY

Telix Pharmaceuticals NASDAQ:TLX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CVAC, RLAY, TLX, and LEGN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CVAC, RLAY, TLX, and LEGN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CVAC, RLAY, TLX, and LEGN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CVAC, RLAY, TLX, and LEGN Company Descriptions

CureVac NASDAQ:CVAC

Legend Biotech NASDAQ:LEGN

Relay Therapeutics NASDAQ:RLAY

Telix Pharmaceuticals NASDAQ:TLX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools